TABLE 2.

Cancer of the ovary, fallopian tube and peritoneum: FIGO staging (2014) compared with TNM classification ^a

FIGO (Designate primary: Tov, Tft, Tp, or Tx)	UICC
	T	N	M
Stage
IA	T1a	N0	M0
IB	T1b	N0	M0
IC	T1c	N0	M0
IIA	T2a	N0	M0
IIB	T2b	N0	M0
IIIA	T3a	N0	M0
	T3a	N1	M0
IIIB	T3b	N0	M0
	T3b	N1	M0
IIIC	T3c	N0−1	M0
	T3c	N1	M0
IV	Any T	Any N	M1
Regional nodes (N)
Nx	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Regional lymph node metastasis
Distant metastasis (M)
Mx	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis (excluding peritoneal metastasis)

1. The primary site—that is, ovary, fallopian tube, or peritoneum—should be designated where possible. In some cases, it may not be possible to clearly delineate the primary site, and these should be listed as “undesignated”.

2. The histologic type should be recorded.

3. The staging includes a revision of the Stage III patients and allotment to Stage IIIA1 is based on spread to the retroperitoneal lymph nodes without intraperitoneal dissemination, because an analysis of these patients indicates that their survival is significantly better than those who have intraperitoneal dissemination.

4. Involvement of retroperitoneal lymph nodes must be proven cytologically or histologically.

5. Extension of tumor from omentum to spleen or liver (Stage IIIC) should be differentiated from isolated parenchymal splenic or liver metastases (Stage IVB).

^a Source: Prat J. ¹⁷